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Abstract
Background: Corticotropin-Releasing Hormone (CRH) testing is used to evaluate suspected adrenocorticotropic
hormone (ACTH) deficiency, but the clinical characteristics that affect response in young children are incompletely
understood. Our objective was to determine the effect of age and body size on cortisol response to CRH in
children at risk for ACTH deficiency referred for clinical testing.
Methods: Retrospective, observational study of 297 children, ages 30 days – 18 years, undergoing initial, clinically
indicated outpatient CRH stimulation testing at a tertiary referral center. All subjects received 1mcg/kg corticorelin
per institutional protocol. Serial, timed ACTH and cortisol measurements were obtained. Patient demographic and
clinical factors were abstracted from the medical record. Patients without full recorded anthropometric data,
pubertal assessment, ACTH measurements, or clear indication for testing were excluded (number remaining = 222).
Outcomes of interest were maximum cortisol after stimulation (peak) and cortisol rise from baseline (delta).
Bivariable and multivariable linear regression analyses were used to assess the effects of age and size (weight,
height, body mass index (BMI), body surface area (BSA), BMI z-score, and height z-score) on cortisol response while
accounting for clinical covariates including sex, race/ethnicity, pubertal status, indication for testing, and time of
testing.
Results: Subjects were 27 % female, with mean age of 8.9 years (SD 4.5); 75 % were pre-pubertal. Mean peak
cortisol was 609.2 nmol/L (SD 213.0); mean delta cortisol was 404.2 nmol/L (SD 200.2). In separate multivariable
models, weight, height, BSA and height z-score each remained independently negatively associated (p < 0.05) with
peak and delta cortisol, controlling for indication of testing, baseline cortisol, and peak or delta ACTH, respectively.
Age was negatively associated with peak but not delta cortisol in multivariable analysis.
Conclusions: Despite the use of a weight-based dosing protocol, both peak and delta cortisol response to CRH are
negatively associated with several measures of body size in children referred for clinical testing, raising the question
of whether alternate CRH dosing strategies or age- or size-based thresholds for adequate cortisol response should
be considered in pediatric patients, or, alternatively, whether this finding reflects practice patterns followed when
referring children for clinical testing.
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Background
Undiagnosed adrenal insufficiency can be life-threatening
[1–3]. Children exposed to prolonged courses of exogen-
ous glucocorticoids or with congenital or acquired forms
of hypopituitarism are at increased risk for adrenocortico-
tropic hormone (ACTH) deficiency, or central adrenal in-
sufficiency [1, 4]. Despite considerable clinical experience,
the diagnosis of ACTH deficiency remains complex [5],
and the “optimal” method to reliably diagnose ACTH defi-
ciency remains unclear [6], particularly in children. While
the insulin tolerance test (ITT) is often considered a “gold
standard,” its use is limited due to the potential for severe
hypoglycemia and its contraindication in patients with a
history of seizures or cardiovascular disease [7, 8]. Al-
though frequently used, the low-dose ACTH stimulation
test does not allow for direct measurement of pituitary re-
sponse, and concerns have been raised about the difficulty
of reliably diluting the low dose of medication with preci-
sion [9]. The standard-dose ACTH stimulation test may
be used to assess for primary adrenal insufficiency, but the
large dose of 250 mcg produces supra-physiologic ACTH
levels, which may lead to falsely reassuring cortisol
responses in patients who may truly have inadequate re-
sponses to stress under more physiologic conditions [9].
Stimulation of the pituitary with corticotropin-releasing
hormone (CRH), or corticorelin, can be used to test for
both primary and secondary adrenal insufficiency through
its stimulation of the release of ACTH from the pituitary
[10–12]. The CRH stimulation test has been suggested as
a useful and safe alternative to the ITT, as the corti-
sol response to CRH has been found to be signifi-
cantly correlated with cortisol response to insulin-
induced hypoglycemia [13, 14]. However, distinguishing
between “healthy” and “inadequate” cortisol responses to
this test remains a challenge, in part because there is not a
clear consensus from previous studies on the patient-
specific clinical factors that determine peak cortisol, par-
ticularly in children. Indeed, although some pediatric stud-
ies suggest that cortisol response after stimulation with
CRH remains constant with increasing age [12, 15, 16], in
other investigations, cortisol response after stimulation
using other strategies, including low- [4] or standard-dose
[17] ACTH, was negatively associated with age in chil-
dren. The current recommended dosing for CRH is
weight-based, which assumes a comparable pituitary and
adrenal response to this medication across all ages and
sizes. Previously published studies have not systematically
focused on the relationship of body size to CRH response,
particularly in children younger than six years [12, 15, 16].
Children under six years of age, in particular, may differ in
clearance rates of medications due to incomplete matur-
ation of physiologic and enzymatic processes [18]. Thus,
the objective of the present study was to determine the ef-
fect of both age and body size on cortisol response, as
measured by peak cortisol and cortisol rise from baseline
(delta) to a standard CRH test in a cohort of nearly 300




This is a retrospective electronic medical record review of
all children and adolescents referred for outpatient adrenal
stimulation testing with CRH between January 2007 and
April 2013 at The Children’s Hospital of Philadelphia Day
Medicine Unit.
Subjects
Subjects were less than 18 years of age at the time of
testing; neonates (<30 days), most of whom receive clin-
ically indicated adrenal stimulation testing as inpatients,
were excluded. For subjects who underwent multiple
stimulation tests, only the first was used for this analysis.
All subjects underwent stimulation with 1 mcg/kg corti-
corelin (CRH) intravenously, prepared as a solution of
50 mcg corticorelin/mL by our institution’s main phar-
macy. Per standard protocol at our institution, cortisol
and ACTH were measured at baseline and 15, 30, 60,
and 90 min after CRH administration. This study was
reviewed, approved, and granted a waiver of consent by
the Institutional Review Board of The Children’s Hospital
of Philadelphia.
Anthropometric and pubertal data
Height and weight were abstracted from electronic med-
ical record as measured on the day of stimulation test-
ing. If unavailable from the day of the test, heights were
abstracted from the closest Endocrinology clinic visit
that occurred no more than 3 months before or after
stimulation. BSA was calculated using the Mosteller for-
mula [19]. The following additional elements of the
physical examination from the closest Endocrinology
clinic visit within 3 months of stimulation testing were
also abstracted: breast Tanner stage (girls only), testicu-
lar volume and Tanner stage (boys only), and Tanner
stage for pubic hair (both girls and boys). Subjects with-
out either height or weight data or without pubertal
exam were excluded from further analysis; this was 54
out of 297 subjects initially identified to have completed
testing.
Laboratory assessment of ACTH and cortisol values
The main hospital laboratory at the Children’s Hospital
of Philadelphia performed all laboratory testing. Cortisol
and ACTH were measured by chemiluminescence. The
lower limit of detection for cortisol was 1.0 mcg/dL
(30 nmol/L) and for ACTH was 5 pg/mL (1 pmol/L).
For the hospital’s main laboratory, the coefficient of
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variation for the cortisol assay was approximately 3–4 %
and for ACTH was 5 %. (Personal communication with
Tracey G. Polsky, MD, PhD, assistant director of the
Clinical Chemistry Laboratory, The Children’s Hospital
of Philadelphia, February 20, 2015) Subjects without
available ACTH values were excluded from further ana-
lysis (n = 11).
Indication for testing
All outpatient Endocrinology clinic visits within 3 months
before or after stimulation testing were reviewed to deter-
mine the indication for referral for adrenal stimulation
testing. A step-wise hierarchical approach was applied in
order to assign a single, primary indication for each sub-
ject for the purpose of these analyses, even though pa-
tients could have more than one indication for testing.
This is described here and illustrated graphically in Fig. 1.
This categorization approach was developed based on a
comprehensive review of pediatric adrenal insufficiency
[1]. First, all subjects with exogenous glucocorticoid ex-
posure noted as an indication for testing were assigned
“exogenous glucocorticoid exposure” as their primary in-
dication for testing. For remaining subjects, if short stat-
ure was listed as an indication for testing, they were
categorized as either “concern for isolated growth hor-
mone deficiency,” or “concern for multiple pituitary ab-
normalities (excluding neoplasm),” depending on whether
the medical history or imaging suggested a possibility of
multiple pituitary abnormalities. Many of these patients
underwent CRH stimulation testing as well as growth hor-
mone (GH) stimulation testing. Subjects who subse-
quently had a likely inadequate response to growth
hormone stimulation testing (GH <10 mcg/L) [20] were
classified into “possible growth hormone insufficiency.”
Those with GH peak ≥ 10 mcg/L were considered to have
“growth hormone sufficient short stature;” these subjects
had apparently intact pituitary GH axis and no other indi-
cation of abnormal pituitary function aside from short
stature. Next, the remaining subjects who did not have
short stature listed as an indication for testing were cate-
gorized into one of the following groups: “neoplastic
process with condition or therapy placing patient at risk
for pituitary injury” or “known multiple pituitary abnor-
mality.” No subjects were suspected of having primary ad-
renal insufficiency. Subjects without documentation of
concern for central adrenal insufficiency as the indication
for testing were excluded from further analysis (n = 10),
for a final subject total of 222.
Statistical analysis
“Peak cortisol” was defined as the maximum observed
cortisol value measured following CRH administration.
Change in cortisol, or “Δ cortisol,” was defined as the dif-
ference between the baseline and peak cortisol. Cortisol
values below the detection limit of 1 mcg/dL were re-
corded as 1 mcg/dL for the purpose of data analysis. Units
were converted to SI using the standard conversions of
27.59 nmol/L per 1.0 mcg/dL cortisol and 0.22 pg/mL per
1.0 pmol/L ACTH. Descriptive variables were summa-
rized by mean ± standard deviation (SD), and outcome
variables by mean ± standard error of the mean (SEM) un-
less otherwise stated. Categorical variables, including pu-
bertal stage, were assessed across groups and sex using
the chi-square test. Peak cortisol was assessed across
weight and age quartiles using one-way ANOVA. Baseline,
delta, and peak cortisol and ACTH were assessed across
indication for testing using one-way ANOVA. Rate of
peak cortisol < 500 nmol/L was compared across indica-
tions and age category (six years or younger vs older than
six years) using the chi-square test. Two-sample t-test was
used to compare the groups with suspected GH deficiency
(those found to be likely GH sufficient and those likely to
Fig. 1 Categorization of indication for adrenal stimulation testing. Indications were extracted from outpatient Endocrinology notes; for many
patients, more than one indication existed
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have GHD) and to compare cortisol response of subjects
categorized by age younger than six years or older. Z-
scores for height and BMI were calculated using CDC
2000 growth standards for children 2 years and older and
WHO 2006 growth standards for children younger than
2 years, as recommended by the CDC [21]. To assess any
potential confounding effect on the outcomes of interest
(laboratory parameters of the CRH stimulation test, in-
cluding peak cortisol, baseline cortisol, and Δ cortisol),
bivariable linear regression analysis was first performed
for covariates of interest, including: age, size (as measured
by weight, height, BMI, BSA, BMI z-score, and height z-
score), indication for testing, baseline cortisol, pubertal
status, race/ethnicity, and time of day (AM or PM). Fac-
tors with p-value of <0.2 were included in multivariable
linear regression models for peak and delta cortisol. Next,
backward elimination using p < 0.1 was used to determine
final multivariable models for peak and delta cortisol. Each
model included only one “size factor” (i.e., weight, height,
BMI, or BSA) or age due to the strong positive correlation
(p < 0.0005) between age and each of weight, height, BMI,
and BSA. BMI z-score and height z-score were also in-
cluded in separate models because z-scores were deter-
mined using both age and absolute height or BMI. Thus,
to avoid the collinearity problem, only one of each of age
or “size factors” was included per model. Of note, weight,
height, BMI, BSA are absolute size factors, while BMI z-
score and height z-score are calculated based on reference
values for age and sex, and thus are relative size factors.
Data analysis was performed with Stata, Release 13.0
(College Station, TX) and R version 3.0.0. A two-sided
p value of <0.05 was considered statistically significant.
Results
Subjects
Table 1 shows subject characteristics, summarized by in-
dication for testing. The 222 subjects (27 % female) who
met inclusion criteria had a mean age of 8.9 years (SD
4.5, range 0.4–17.8 years). Seventy-five percent were
pre-pubertal (Tanner I), 22 % were peri-pubertal (Tanner
II-IV), and 4 % were post-pubertal (Tanner V). These
proportions were not significantly different between boys
and girls (p = 0.07). Seventy-nine percent of subjects did
not have pubic hair at time of stimulation testing. By
body mass index (BMI) z-score, 26 % of subjects were
overweight or obese (BMI z-score ≥1.04) [21]. As ex-
pected in a population including glucocorticoid-treated
children, as well as those with known pituitary abnor-
malities and/or clinically referred for short stature, sub-
jects were relatively short (mean height z-score −1.96,
range −6.07 to 3.2). Subjects with known multiple pituit-
ary abnormalities tended to be older and weighed more
than those who were undergoing initial evaluation for
pituitary abnormalities (p < 0.0005 for both; see Table 1).
Additionally, for each group, the majority of subjects
were male. This was most notable for the group with
neoplasms with risk to the pituitary. The two groups of
subjects screened for growth hormone deficiency (GHD)
were similar in age, weight, height, and gender distribu-
tion (p > 0.05), and 49 % of those tested for GHD had
peak growth hormone of < 10 mcg/L.
Cortisol and ACTH response to stimulation
Mean peak cortisol for all subjects was 609.2 nmol/L
(SD 213.0, range 27.59–1404.3). Mean Δ cortisol was



















n 35 33 52 50 35 17 -
Sex
(% female)
34 % 27 % 29 % 16 % 34 % 29 % 0.4
Age (years) 9.1 (4.6) 8.4 (4.1) 7.3 (5.0) 10.1 (3.0) 8.1 (4.9) 12.6 4.2) 0.0002
Tanner stage (Breast/Genital)
I 28 (80 %) 29 (88 %) 44 (85 %) 33 (66 %) 25 (71 %) 7 (41 %) <0.0005
II–IV 7 (20 %) 4 (12 %) 7 (13 %) 17 (34 %) 6 (17 %) 7 (41 %)
V 0 0 1 (2 %) 0 4 (11 %) 3 (18 %)
Presence of pubic hair
No 29 (83 %) 32 (97 %) 47 (90 %) 32 (64 %) 27 (77 %) 8 (47 %) <0.0005
Yes 6 (17 %) 1 (3 %) 5 (10 %) 18 (36 %) 8 (23 %) 9 (53 %)
Weight (kg) 23.6 (11.1) 24.5 (14.2) 25.9 (17.4) 31.8 (13.1) 31.0 (22.9) 47.5 (22.4) <0.0005
BMI z-score −0.50 (0.98) −0.04 (1.25) 0.55 (1.12) 0.27 (1.05) 0.45 (1.36) 0.57 (1.53) 0.0009
Height z-score −2.8 (0.8) −2.6 (0.9) −1.8 (1.6) −1.6 (1.4) −1.4 (1.3) −1.6 (1.5) <0.0005
Data are presented as mean (SD)
aAs determined by ANOVA across indication for testing
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404.2 nmol/L (SD 200.2, range 0–905.0). Using cortisol
of 500 nmol/L, a commonly used threshold to define
“failure” to achieve reassuring cortisol response to CRH
stimulation [6, 22], failure rate varied significantly by in-
dication for testing (p = 0.0066 by ANOVA). Fourty-
eight (22 %) of all subjects had peak cortisol less than
500 nmol/L. The greatest failure rate occurred in the
group tested due to exogenous glucocorticoid exposure;
this group had 63 % (22/35) of subjects with peak corti-
sol < 500 nmol/L.
Mean peak ACTH for all subjects was 20.2 pmol/L
(SD 18.7, range 1.1–197.8). Mean baseline ACTH was
4.1 pmol/L (SD 3.6, range 1.1–30.4); mean delta ACTH
was 16.1 pmol/L (SD 18.2, range 0–192.5). Mean peak
ACTH for subjects with peak cortisol less than
500 nmol/L was 11.4 pmol/L (SD 9.0, range 1.1–36.3),
compared to mean peak ACTH of 22.6 pmol/L (SD 19.9,
range 3.6–197.8) for subjects with peak cortisol of
500 nmol/L or greater. This difference was statistically
significant (p = 0.0002 by two-sample t-test).
Relationship between cortisol response, body size, age,
and other clinical covariates
Table 2 displays results of bivariable analysis of factors
predicted to have a potential effect on peak or delta cor-
tisol. In bivariable analysis, peak cortisol was signifi-
cantly negatively associated with age, weight, height,
BMI, BSA, and height z-score (p < 0.05 for each). Nega-
tive associations between body size factors and delta cor-
tisol were also found but were less robust, with only
height z-score reaching a similar level of statistical sig-
nificance (p < 0.05). For purposes of further investigation
of the relationship between outcomes with the predictive
factors, factors with p-value < 0.2 were included in multi-
variable analysis and noted in Table 2, as described in
Methods; for delta cortisol, these factors included
weight, height, and BSA. Unlike for peak cortisol, age
was not correlated with delta cortisol (p > 0.2). Base-
line cortisol was significantly positively correlated with
peak cortisol and negatively correlated with delta cortisol
(p < 0.0005 for each). Baseline ACTH (p = 0.007), delta
ACTH (p < 0.0005), and peak ACTH (p < 0.0005) were
significantly positively correlated with peak cortisol. Delta
and peak ACTH were also significantly positively corre-
lated with delta cortisol (p < 0.0005 for each) (Table 2). To
assess for bias conferred by subjects considered to have
central cortisol deficiency, sensitivity analysis was per-
formed. In bivariable analysis excluding subjects with peak
cortisol < 500 nmol/L, age and size variables of interest
(weight, height, BSA, and height z-score) remained signifi-
cantly negatively associated with peak cortisol (p < 0.05).
BMI also remained negatively associated with peak corti-
sol (p = 0.13) (data not shown).
Other factors with marginal significance (p < 0.2) in
bivariable analysis of peak cortisol were sex (male vs fe-
male, p = 0.182) and time of testing (after vs before
12:00 PM, p = 0.17); both factors were negatively associ-
ated with peak cortisol. For delta cortisol, ethnicity
(Hispanic/Latino vs non-Hispanic/Latino, p = 0.09) and





Coefficient p-value Coefficient p-value
Age (years) −7.6 0.02* NS
Weight (kg) −2.5 0.002 ** −1.4 0.06#
Weight inverse (1/kg) 1153.9 0.004 ** NS
Height (m) −174.1 0.001 ** −85.9 0.08#
BMI (kg/m2) −6.5 0.04* NS
BSA (m2) −123.8 0.001 ** −67.4 0.05#
BMI z-score −14.6 NS NS
Height z-score −41.7 <0.0005** −33.4 <0.005**









Tanner II-IV NS NS



















−312.7 <0.0005** −239.0 <0.0005**
Known multi-pituitary
abnormalities
−133.7 0.02* −105.3 0.05
Time of testing
(PM vs AM)
−40.1 0.17# −62.2 0.02*
Baseline cortisol
(nmol/L)
0.72 <0.0005** −0.35 <0.0005**
Baseline ACTH (pmol/L) 10.6 0.01* −5.9 0.11#
Delta ACTH (pmol/L) 3.4 <0.0005** 4.0 <0.0005**
Peak ACTH (pmol/L) 3.6 <0.0005** 3.6 <0.0005**
#p-value <0.2 (for use in multivariate analysis); *p-value;<0.05,
**p-value < 0.005
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time of testing (after vs before 12:00 PM, p = 0.023)
were significantly negatively correlated. Pubertal status
(post-pubertal vs pre-pubertal: p = 0.003) was signifi-
cantly negatively correlated with delta cortisol but not
peak cortisol. These factors were included in initial
multivariable models for peak and delta cortisol.
For peak and delta cortisol, indication for testing was
associated with cortisol response (p < 0.0005). To ac-
count for this in multivariable linear regression, inter-
action terms between indication for testing and the size
variable of interest were created and included in each
model.
Multivariable model for peak cortisol response to
stimulation
Multivariable linear regression analysis was used to de-
termine factors that were independently associated with
cortisol response to CRH stimulation. Table 3 displays
final multivariable linear regression models obtained
after backward elimination of non-significant (p > 0.1) var-
iables that were initially included from bivariable analysis.
Baseline cortisol and peak ACTH remained significantly
positively associated with peak cortisol. Sex was mar-
ginally associated with peak cortisol in each multivari-
able model, with p-values ranging from 0.048 for the
model including age to 0.057 for the model including
height z-score. Each model also included interaction
terms between indication for testing and either age or
the size factor of interest. Because age and size are
highly associated, only one of these was included in each
model to avoid collinearity, as described in Methods.
Models for weight, height z-score, and BSA included
significant interaction terms between indication for test-
ing and size. For these models, an interaction between
size and exogenous glucocorticoid administration was
detected (p < 0.05); within glucocorticoid-exposed chil-
dren, the smallest children seemed to have the lowest
peak cortisol, as described in more detail below. Multi-
variable linear regression analysis was repeated separ-
ately for the group with exogenous glucocorticoid
exposure (Additional file 1: Table S1). In this analysis,
the exogenous glucocorticoid group did not have an in-
dependent association between peak cortisol and weight
or BSA (p > 0.05), but did have a significant positive
Table 3 Multivariable models for peak cortisol
Age (years) Weight (kg) Height (m) BSA (m2) Height z-score
Coefficient p-value Coefficient p-value Coefficient p-value Coefficient p-value Coefficient p-value
Age or size factor −6.6 0.01* −5.9 0.01* −135.3 0.001 ** −221.3 0.01* −70.8 0.02*
Sex (vs female) −46.4 0.05* −45.7 0.05 −45.1 0.05 −45.2 0.06
Indication for testing (vs GH sufficient short stature)
GHD NS NS NS NS NS
Concern for multi-pituitary
abnormalities
−67 0.05* −137 0.06 −63 0.06 −173 0.07 NS
Neoplasm with risk to
pituitary
NS NS NS NS NS
Exogenous glucocorticoid
exposure
−249 <0.0005** −398 <0.0005** −242 <0.0005** −425 <0.0005** NS
Known multi-pituitary
abnormalities
−104 0.02* −244.0 0.03* −94 0.04* NS NS
Interaction variables (vs GH sufficient group*age or size factor)
GHD*(age or size factor) NS NS NS
Concern for multi-
pituitary*(age or size factor)
NS NS NS








Baseline cortisol (nmol/L) 0.59 <0.0005** 0.60 <0.0005** 0.58 <0.0005** 0.60 <0.0005** 0.65 <0.0005**
Peak ACTH (pmol/L) 2.56 <0.0005** 2.49 <0.0005** 2.47 <0.0005** 2.49 <0.0005** 2.20 <0.0005**
R2, n 0.5092, 222 0.5201, 222 0.5182, 222 0.5196, 222 0.5481, 222
*p-value <0.05, **p-value < 0.005 by multivariate linear regression
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association between peak cortisol and height z-score
(beta = 58.6, p = 0.015), opposite the direction of the
negative association between size and peak cortisol over
all other subjects.
Multivariable model for delta cortisol
Table 4 displays final multivariable linear regression
models obtained after backward elimination of non-
significant (p > 0.1) variables that were initially included
from bivariable analysis with delta cortisol. In the final
multivariable models, pubertal status, ethnicity, and time
of stimulation testing were no longer significantly inde-
pendently associated with delta cortisol. Baseline cortisol
remained significantly negatively and delta ACTH sig-
nificantly positively associated with delta cortisol.
Similar to the models for peak cortisol, each model of
delta cortisol included interaction terms between indica-
tion for testing and the size factor of interest, as described
above. Models for weight, BSA, and height z-score in-
cluded significant interaction terms between indication for
testing and size. Again, for these models, the association
between delta cortisol and size (weight, BSA, or
height z-score) among subjects tested due to exogenous
glucocorticoids was positive, opposite that of overall sub-
jects. Similar to the findings for peak cortisol, when ana-
lysis of delta cortisol was repeated by indication for
testing, a significant positive association (p = 0.003) be-
tween height z-score (but not weight or BSA) and delta
cortisol was found for subjects with exogenous gluco-
corticoid exposure (data shown in Additional 2: Table S2).
Relationship between weight, age and peak cortisol
response
Figure 2 displays peak cortisol response by quartiles of
absolute weight. As shown, subjects in the highest
weight quartile tended to have the lowest peak cortisol,
consistent with the negative correlation found on multi-
variable regression. By one-way ANOVA, peak cortisol
differed significantly across weight quartiles (p = 0.0076).
In the highest weight quartile, 36 % (20/55) of subjects
failed to achieve a peak cortisol of 500 nmol/L, as opposed
to 17 % (28/167) of subjects in quartiles 1–3 (p = 0.002 by
chi-square test). To better understand the interaction be-
tween weight, age, and cortisol response, this analysis was
repeated by age quartile, and no significant difference in
peak cortisol across age quartiles was noted (p > 0.05, data
not shown).
Relationship between peak and baseline cortisol and time
of testing
Although mean baseline cortisol drawn between 8:00
and 9:00 AM tended to be higher than those drawn after
9:00 AM (226.2 nmol/L, SD 88.0 for 12 subjects vs
200.2 nmol/L, SD 148.2 for 206 subjects), this did not
reach statistical significance (p = 0.5). Peak cortisol also
did not differ significantly between these groups (mean
peak 562.8 nmol/L, SD 171.4 vs 610.0 nmol/L, SD 216.6,
Table 4 Multivariable models for delta cortisol
Weight Height BSA (m2) Height z-score
Coefficient p-value Coefficient p-value Coefficient p-value Coefficient p-value
Size factor −5.8 0.02* −128.3 0.003 ** −216.8 0.02 −71.5 0.02*
Indication for testing (vs GH sufficient short stature)
GHD NS NS NS NS
Concern for multi-pituitary abnormalities NS NS NS NS
Neoplasm with risk to pituitary NS NS NS NS
Exogenous glucocorticoid exposure −429 <0.0005** −256 <0.0005** −472 <0.0005** NS
Known multi-pituitary abnormalities −230.0 0.05* −96 0.05* NS NS
Interaction variables (vs GH sufficient group*size factor)
GHD*(size factor) NS NS NS
Concern for multi-pituitary*(size factor) NS NS NS
Neoplasm*(size factor) NS NS NS
Exogenous glucocorticoids*(size factor) 7.0 0.01* 245.5 0.03* 159 <0.0005**
Known multi-pituitary*(size factor) NS NS NS
Baseline cortisol (nmol/L) −0.44 <0.0005** −0.46 <0.0005** −0.44 <0.0005** −0.40 <0.0005**
Delta ACTH (pmol/L) 2.47 <0.0005 2.49 <0.0005** 2.49 <0.0005** 2.22 <0.0005**
R2, n 0.3956, 222 0.3875, 22 0.3947, 222 0.4621, 222
*p-value <0.05, **p-value < 0.005 by multivariate linear regression
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p = 0.5). Similarly, when divided into subjects tested be-
fore and after noon, baseline cortisol did not differ sig-
nificantly (192.0 nmol/L, SD 106.6 for 117 subjects vs
212.9 nmol/L, SD 180.3 for 101 subjects, p = 0.3).
Baseline and peak cortisol response in children six years
or younger
We sought to characterize cortisol response in children
6 years and younger, as limited data is available for chil-
dren of this age referred for clinical testing. Baseline cor-
tisol was significantly higher in children 6 years or
younger (239.4 nmol/L, SD 172.0 for 57 subjects vs
188.7 nmol/L, SD 132.5 for 165 subjects, p = 0.0223 by
two-sample t-test). Peak cortisol, however, did not sig-
nificantly differ between these groups (652.1 nmol/L, SD
221.8 for 57 subjects vs 594.4 nmol/L, SD 208.5 for 165
subjects, p = 0.08). Rate of peak cortisol response less
than 500 nmol/L also did not differ significantly between
these groups (11/57 (19 %) vs 37/165 (22 %), p = 0.6 by
chi-square).
Relationship between weight, indication for testing, and
peak cortisol
To better understand the interaction between weight
and indication for testing in the multivariable model for
peak cortisol, subjects who “failed” (peak cortisol <
500 nmol/L) CRH stimulation were compared across
weight quartiles and indication for testing, as shown in
Fig. 3. As shown, the group with exogenous glucocortic-
oid exposure had significantly higher rates of failure,
particularly for the middle two weight quartiles. A sum-
mary of failure rates for all groups is shown in black; this
demonstrates the trend across groups toward higher fail-
ure rates among the highest weight quartile. Overall fail-
ure rates for each indication for testing are summarized
in Table 5.
Finally, to minimize effects of indication of testing on
cortisol response, bivariable analysis was repeated for
the two groups with the most similar subjects: those
tested due to concern for GHD and subsequently found
to be either likely GH sufficient or deficient. These
groups had similar weight and age distributions (p = 0.79
and p = 0.50 by two-sample t test). In this analysis, the
negative association between weight and peak cortisol
(p = 0.008) and age and peak cortisol (p = 0.021) per-
sisted, suggesting that the differences among subjects
due to indication for testing cannot solely explain the
negative correlation between body size or age and corti-
sol response.
Discussion
In both bivariable and multivariable analyses, peak corti-
sol after CRH stimulation testing was significantly nega-
tively associated with age and multiple measures of body
Fig. 2 Peak cortisol response to CRH stimulation by weight quartile over the entire cohort. N = 222 (quartile 1: n = 57, quartile 2: n = 54, quartile 3:
n = 56, quartile 4: n = 55). Dotted line represents a commonly used threshold for stimulation test failure, cortisol of 500 nmol/L. ** p-value = 0.003
for quartile 4 vs quartile 1 after Bonferroni correction
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size, including weight, height, height z-score, and BSA in
our study of over 200 children referred for clinical test-
ing. Delta cortisol, another measure of cortisol response
to stimulation, was similarly negatively associated with
weight, height, height z-score, and BSA, but was not sig-
nificantly associated with age.
These findings may be interpreted in several ways.
First, due to the retrospective nature of our study, refer-
ral bias may have played a role. For example, the high
failure rate among glucocorticoid-exposed subjects may
be due to referral of the most severely affected individ-
uals, raising the pre-test probability of failure. Addition-
ally, younger (and smaller) subjects may have been
referred more readily despite their relatively healthy clin-
ical status, making these subjects more likely to pass
their stimulation test. Another possibility is the changing
nature of indication for testing across age and size. For
example, older and larger subjects may have been tested
for indications that also increased their pre-test prob-
ability of failure, independent of their size and age. To
account for these possibilities, we performed several sen-
sitivity analyses. As explained above in Results, when
bivariable analysis was repeated only for subjects tested
due to concern for isolated growth hormone deficiency,
the negative association between peak cortisol and
weight or age persisted. Therefore, another important
Fig. 3 Failure rate (rate of peak cortisol < 500 nmol/L), by absolute weight quartile and indication for testing. Error bars represent 95 % confidence
intervals. Total subjects are represented by the black line. Indication for testing was numbered as follows: 1. GH sufficient short stature (n = 35); 2.
Probable GHD (n = 33); 3. Concern for multiple pituitary abnormalities (n = 52); 4. Neoplasm with risk to pituitary (n = 50); 5. Exogenous glucocorticoid
exposure (n = 35); 6. Known multiple pituitary abnormalities (n = 17); 7. All indications (n = 222)
Table 5 Cortisol and ACTH response by indication for testing


















n 35 33 52 50 35 17
Baseline cortisol (nmol/L) 231.0 (124.3) 203.3 (136.6) 221.1 (182.0) 199.1 (119.4) 145.7 (139.8) 202.2 (139.6) 0.18
Delta cortisol (nmol/L) 454.9 (168.1) 485.2 (139.7) 399.8 (160.4) 470.2 (189.2) 215.9 (218.4) 349.6 (219.5) <0.0005
Peak cortisol (nmol/L) 685.9 (161.8) 688 .5 (179.8) 620.9 (178.6) 675.8 (138.5) 373.2 (246.1) 552.2 (227.0) <0.0005
Baseline ACTH (pmol/L) 3.2 (1.8) 5.9 (6.6) 4.2 (2.6) 3.6 (1.9) 3.7 (4.1) 4.7 (2.8) 0.036
Delta ACTH (pmol/L) 14.9 (9.3) 23.0 (18.5) 13.2 (11.6) 21.4 (26.6) 6.3 (4.9) 18.3 (25.6) 0.0007
Peak ACTH (pmol/L) 18.1 (9.6) 28.9 (17.9) 17.4 (11.5) 25.0 (27.0) 10.1 (7.5) 23.0 (26.3) 0.0003
Failure Rate (peak cortisol <
500 nmol/L)
11.4 % 9.1 % 21.2 % 6.0 % 62.9 % 29.4 % <0.0005
Data are presented as mean (SD)
aAs determined by ANOVA across indication for testing for cortisol and ACTH values; by Chi-square for Failure Rate
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possible explanation to explore is that true physiologic
differences in adrenal response to CRH exist, despite
weight-based dosing, across the wide range of body sizes
and ages of children included in the present study.
An important previous study in healthy children did
not find age- or size-based differences in pharmacoki-
netic or pharmacodynamic parameters in the response
to CRH, but the sample size was relatively small (n = 21,
girls and boys ages 6–15 years), and these investigators
themselves noted the lack of data for children under
6 years of age [16]. However, in investigations using
other techniques to assess hypothalamic-pituitary-
adrenal axis function (low- and standard-dose ACTH),
peak cortisol response in healthy children [17] and in
children exposed to exogenous glucocorticoids [4] did
decrease with age, consistent with our findings using CRH
stimulation testing over all subjects. As noted previously,
the subjects in our study with glucocorticoid exposure did
not demonstrate a similar negative relationship between
peak or delta cortisol and height z-score (Additional file 1:
Table S1 and Additional file 2: Table S2). This may reflect
the higher likelihood of adrenal suppression in subjects
who had glucocorticoid exposure great enough to nega-
tively affect height growth, as even inhaled corticosteroids
have been associated with decreased height growth, par-
ticularly in prepubertal children [23].
Other studies have also found associations between
cortisol levels and age in healthy children, but the direc-
tion of effect has differed between studies depending on
statistical approaches, highlighting how the simultaneous
effects of age and size are challenging to disentangle
[24–27]. For example, in one of these investigations, sal-
ivary cortisol concentration was initially found to in-
crease with age, but after statistical adjustment for BSA,
the relationship with age seemed reversed [25]. The au-
thors posit that this finding could reflect a lower produc-
tion rate or higher rate of clearance of cortisol with age
[25]. A separate study focused on this question found
that daily cortisol production remained constant with
age, again after adjustment for body surface area [28].
Taken together, these studies illustrate the important
challenge in pediatrics of scaling for size when interpret-
ing experimental results across a wide range of subject
ages [29], particularly in the youngest children, in whom
there is the additional complexity of incomplete matur-
ation of kidney and liver function, which also affects
drug metabolism [30].
To our knowledge, an independent, negative relation-
ship between cortisol response to CRH and body size
has not been demonstrated previously. As discussed
above, due to the high correlation between age and body
size, discerning the relative effects on cortisol response
of each of these is a challenging undertaking, particularly
due to differences in indication for testing across age
and weight. For example, the association between peak
cortisol response and age/size may be due to matur-
ational differences in the responsiveness of the adrenal
gland to ACTH and/or clearance of cortisol, differences
that cannot be fully adjusted by the current weight-
based dosing regimen of CRH.
Differences in adrenal gland size may also partly ex-
plain differences in responsiveness across the ages and
body sizes tested. The adrenal gland does not grow at
the same pace as the rest of the body; instead, it de-
creases in size from birth to around one year of age,
then gains mass, but more slowly than the body as a
whole [31]. If circulating cortisol concentration were to
remain constant or even increase with age as has been
described by several authors [24–26], these relatively
smaller adrenal glands would need to produce proportion-
ally more cortisol to distribute across relatively larger
blood volumes, assuming constant clearance. Although
these relatively smaller adrenal glands would thus produce
larger amounts of cortisol relative to body size on a con-
stant basis, they may not produce as robust a response to
acute stimulation, as they may already be operating at a
“higher capacity.” This “lower reserve” could explain the
lower peak cortisol response to stimulation in subjects
with larger body surface area and relatively smaller adrenal
glands.
Alternatively, age may be the driving force in the nega-
tive association, through mechanisms not primarily
driven by body size. We looked for but did not find an
effect of puberty and/or presumed adrenarche (pubic
hair development alone) on cortisol response, but the
sample was enriched in young, pre-pubertal children, so
these effects may have been more difficult to detect. In-
deed, at least one previous study has suggested increased
volume of distribution and more rapid clearance of cor-
tisol with the onset of puberty [32]. Sampling beyond
the usual prescribed time range for CRH stimulation
testing would be required to estimate these parameters.
Additional careful pharmacokinetic and pharmaco-
dynamics studies in children could help answer these
questions.
Strengths and limitations
The strengths of the present study include its large size
and wide range of ages studied, including 57 children
age six years and younger, the largest study to our know-
ledge of children in this age range who have undergone
stimulation with CRH. As mentioned above, our study
has limitations related to its retrospective nature. One
potential limitation was the health status of our subjects,
who had a wide range of diagnoses and exposures to
medications and therapies. Although this limits our abil-
ity to generalize to healthy children, our subjects are
representative of the patients who most often undergo
Vajravelu et al. International Journal of Pediatric Endocrinology  (2015) 2015:22 Page 10 of 12
adrenal stimulation testing. As noted above, however,
89 % of subjects with presumed growth hormone suffi-
cient short stature reached a cortisol peak of 500 nmol/L,
consistent with our belief that this group was representa-
tive of subjects with a likely intact HPA axis, regardless of
their short stature. In addition, we considered the possibil-
ity that age- or size-related differences in indication for
testing could introduce bias into our results. We observed
the negative association between peak cortisol and age or
size even in multivariable regression analyses including
testing indication and interaction terms between testing
indication and age/size (Table 3). However, it would be
optimal to reproduce these results in additional cohorts
prospectively grouped by age and indication for testing
and to consider studies in healthy children as well.
Additionally, referral patterns may be valuable to
study, as one interpretation of our results may be that
younger/smaller children with intact adrenal function
may be more likely to undergo testing to exclude
ACTH deficiency as part of an initial evaluation. This
may explain our finding that smaller, shorter children
tended to have higher peak cortisol, opposite of what
one would expect if these children were short due to
underlying pathology associated with ACTH defi-
ciency. Finally, an additional limitation is that cumu-
lative glucocorticoid exposure was unavailable for
analysis; although this was not the primary focus of
our study, it may have allowed for a better under-
standing of the cortisol response among this group of
subjects.
The present study, the largest collection to date of
pediatric CRH stimulation testing results to our know-
ledge, demonstrates that cortisol response to CRH
stimulation is negatively associated with both age and
size, as reflected by weight, height, BSA, and height z-
score, in children referred for clinical testing, even after
accounting for important clinical covariates. Additional
careful pharmacokinetic and pharmacodynamic studies,
including serial measurements of CRH, ACTH, and cor-
tisol, could help clarify the etiology of these differences.
That is, the volume of distribution of CRH, and/or the
clearance of cortisol are at least two potential sources of
age- or size-related variation.
Conclusions
Our results suggest that to better interpret peak cortisol
response across a wide range of ages and sizes in the
pediatric population, it may be helpful to consider the
possibility of greater cortisol responses in the youn-
gest and smallest patients. Specifically, for patients
with “borderline” peak cortisol response, it may be helpful
to consider the patient-specific characteristics of age and
size when determining whether the patient has “passed”
or “failed” the stimulation test. Our study was limited to a
population referred for clinical testing, but the potential
for generalizability of these findings make future prospect-
ive studies focused on size and age very important. Opti-
mally, prospective development of age- or size-dependent
thresholds for cortisol response might increase the clinical
utility of this provocative test, particularly in the youngest
at-risk patients.
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